Compare Noble Corporation plc (NE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Zimmer Biomet Holdings Inc — how do they compare? Noble Corporation plc trades at $42.56 (market cap $6.73B), while Zimmer Biomet Holdings Inc trades at $88.84 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.5× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NE | ZBH | |
|---|---|---|
Market Cap | $6.73B | $16.95B |
Volume | 1,027,635 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $54.37 | $103.98 |
52-Week Low | $26.70 | $79.58 |
Typical Hold Time | 26 Days | 89 Days |
Enterprise Value | $8.16B | $24.02B |
Dividend Yield | 4.74% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.56, up 3.88% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with a 4.88% net income margin, though recent quarterly earnings have been inconsistent with two misses and one beat. Analyst sentiment is divided with a $52 consensus price target representing 22% upside potential, but ongoing legal investigations create uncertainty.
The stock presents a moderate opportunity with significant analyst upside potential, supported by recent contract wins including the long-term Ghana drilling agreement. However, risks include inconsistent earnings performance, declining profitability margins from 2025 to 2026, and multiple ongoing legal investigations that could impact investor confidence and stock performance in the near term.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
